Is Halliburton a Good Stock to Buy After Earnings?

Page 1 of 2

Halliburton Company (NYSE:HAL) reported its results for the fourth quarter of 2012 on January 25th. Earnings were down from the fourth quarter of 2012, but even excluding one-time items the EPS figure of 67 cents beat analyst expectations. The stock rose 5% on the day and is currently up 11% year to date. While revenue increased 3% from the fourth quarter of 2011, and also rose on a q/q basis, operating costs particularly in the completion and production segment were considerably higher than a year earlier. Halliburton’s U.S. drilling business has suffered; while onshore oil activity is strong, low natural gas prices- and, in turn, cash crunches at some natural gas producers- have reduced demand for the company’s services on net.

The stock now trades at 13 times trailing earnings, which would generally be a low multiple unless Halliburton Company failed to grow its business over the next several years. Wall Street analyst estimates for 2013 imply a current-year P/E of 10, and expectations of continued growth beyond that point result in a five-year PEG ratio of 0.9. It is the case that markets are generally pricing many large oil related companies low- the oil majors themselves tend to be trading at about 10 times earnings or even lower- and so perhaps in the context of the sector this earnings multiple is not particularly attractive. However, if it is the case that Halliburton has less exposure to commodity prices or has other secular factors in its favor, that might explain the gap there and certainly it would be difficult to call it overvalued at these prices.

OMEGA ADVISORS

Halliburton was one of the ten most popular energy stocks among hedge funds in the third quarter of 2012 (see the full top ten list) as 50 hedge funds and other notable investors in our database of 13F filings reported a position in the company. Billionaire Leon Cooperman’s Omega Advisors increased its holdings of Halliburton Company by 26% during the third quarter of 2012 and reported owning 3.3 million shares at the end of September (check out Cooperman’s stock picks). The company was one of ValueAct Capital’s ten largest holdings at the end of the quarter; ValueAct is managed by Jeffrey Ubben (find more of ValueAct’s favorite stocks). Steadfast Capital Management, managed by Robert Pitts, initiated a position of 2.6 million shares.

How does Halliburton compare to its peers?

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!